CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 2, 2013, Pages 195-203

  Musumba, C O ^a,b   Jorgensen, A ^a   Sutton, L ^a   Van Eker, D ^a,b   Zhang, E ^a   O'Hara, N ^a   Carr, D F ^a   Pritchard, D M ^a,b   Pirmohamed, M ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DICLOFENAC; ESOMEPRAZOLE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; LORNOXICAM; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXICAM DERIVATIVE; PANTOPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; STEROID; STOMACH SECRETION INHIBITOR; CYP2C19 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DRUG MEGADOSE; DUODENUM ULCER; ENZYME ACTIVITY; FEMALE; GAIN OF FUNCTION MUTATION; GENE CLUSTER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HELICOBACTER INFECTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING; WILD TYPE; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL HEMORRHAGE; GENETICS; MULTICENTER STUDY; RISK; STATISTICAL MODEL; UNITED KINGDOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HELICOBACTER INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PEPTIC ULCER; POLYMORPHISM, SINGLE NUCLEOTIDE;

MLCS; MLOWN;

EID: 84872683172     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.215     Document Type: Article

References (50)

1. Blanco, G. et al. Interaction of CyP2C8 and CyP2C9 genotypes modifes the risk for nonsteroidal anti-infammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet. Genomics 18, 37-43 (2008).
2. Carbonell, N. et al. CyP2C9*3 Loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin. Pharmacol. Ther. 87, 693-698 (2010).
3. Ma, J., Yang, X.Y., Qiao, L., Liang, L.Q. & Chen, M.H. CyP2C9 polymorphism in non-steroidal anti-infammatory drugs-induced gastropathy. J. Dig. Dis. 9, 79-83 (2008).
4. Martin, J.H., Begg, E.J., Kennedy, M.A., Roberts, R. & Barclay, M.L. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br. J. Clin. Pharmacol. 51, 627-630 (2001).
5. Pilotto, A. et al. Genetic susceptibility to nonsteroidal anti-infammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133, 465-471 (2007).
6. Vonkeman, H.E., van de Laar, M.A., van der Palen, J., Brouwers, J.R. & Vermes, I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from the Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther. 28, 1670-1676 (2006).
7. Estany-Gestal, A., Salgado-Barreira, A., Sánchez-Diz, P. & Figueiras, A. Infuence of CyP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-infammatory drugs: a systematic critical review. Pharmacogenet. Genomics 21, 357-364 (2011).
8. Ingelman-Sundberg, M., Sim, S.C., Gomez, A. & Rodriguez-Antona, C. Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
9. Niwa, T., Murayama, N. & Yamazaki, H. Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome. Curr. Drug Metab. 10, 700-712 (2009).
10. Martis, S., Peter, I., Hulot, J.S., Kornreich, R., Desnick, R.J. & Scott, S.A. Multiethnic distribution of clinically relevant CyP2C genotypes and haplotypes. Pharmacogenomics J. (2012); e-pub ahead of print 10 April 2012.
11. Goldstein, J.A. Clinical relevance of genetic polymorphisms in the human CyP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355 (2001).
12. Yasar, U. et al. Linkage between the CyP2C8 and CyP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299, 25-28 (2002).
13. Pedersen, R.S. et al. Linkage disequilibrium between the CyP2C19*17 allele and wildtype CyP2C8 and CyP2C9 alleles: identifcation of CyP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66, 1199-1205 (2010).
14. Suarez-Kurtz, G. Linkage disequilibrium between the CyP2C19*17 and CyP2C8*2 alleles in populations of African descent. Eur. J. Clin. Pharmacol. 67, 211-212 (2011).
15. Harmsze, A.M. et al. The infuence of CyP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet. Genomics 22, 169-175 (2012).
16. Scott, S.A., Martis, S., Peter, I., Kasai, y., Kornreich, R. & Desnick, R.J. Identifcation of CyP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J. 12, 297-305 (2012).
17. Sibbing, D. et al. Isolated and interactive impact of common CyP2C19 genetic variants on the antiplatelet Effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685-1693 (2010).
18. Daily, E.B. & Aquilante, C.L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10, 1489-1510 (2009).
19. Rosemary, J. & Adithan, C. The pharmacogenetics of CyP2C9 and CyP2C19: ethnic variation and clinical signifcance. Curr. Clin. Pharmacol. 2, 93-109 (2007).
20. Scott, S.A. et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet. Genomics 22, 159-165 (2012).
21. Van Booven, D. et al. Cytochrome P450 2C9-CyP2C9. Pharmacogenet. Genomics 20, 277-281 (2010).
22. Baldwin, R.M. et al. Increased omeprazole metabolism in carriers of the CyP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. 65, 767-774 (2008).
23. Hunfield, N.G. et al. Effect of CyP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br. J. Clin. Pharmacol. 65, 752-760 (2008).
24. Sim, S.C. et al. A common novel CyP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006).
25. Shiotani, A. et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J. Gastroenterol. 44, 717-725 (2009).
26. Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C. & Lithgow, J. Pharmacogenetics of CyP2C19: functional and clinical implications of a new variant CyP2C19*17. Br. J. Clin. Pharmacol. 69, 222-230 (2010).
27. Zabalza, M. et al. Meta-analyses of the association between cytochrome CyP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98, 100-108 (2012).
28. Capdevila, J.H., Falck, J.R. & Estabrook, R.W. Cytochrome P450 and the arachidonate cascade. FASEB J. 6, 731-736 (1992).
29. Kaspera, R. & Totah, R.A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin. Drug Metab. Toxicol. 5, 757-771 (2009).
30. Spector, A.A., Fang, X., Snyder, G.D. & Weintraub, N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43, 55-90 (2004).
31. Wray, J. & Bishop-Bailey, D. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp. Physiol. 93, 148-154 (2008).
32. Roman, R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185 (2002).
33. Carroll, M.A., Garcia, M.P., Falck, J.R. & McGif, J.C. 5, 6-epoxyeicosatrienoic acid, a novel arachidonate metabolite. Mechanism of vasoactivity in the rat. Circ. Res. 67, 1082-1088 (1990).
34. Imig, J.D., Navar, L.G., Roman, R.J., Reddy, K.K. & Falck, J.R. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 7, 2364-2370 (1996).
35. Zhu, D. et al. Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am. J. Physiol. Lung Cell Mol. Physiol. 278, L335-L343 (2000).
36. Fang, X. et al. 14, 15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am. J. Physiol. 275, H2113-H2121 (1998).
37. Chehal, M.K. & Granville, D.J. Cytochrome p450 2C (CyP2C) in ischemic heart injury and vascular dysfunction. Can. J. Physiol. Pharmacol. 84, 15-20 (2006).
38. Fleming, I. et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally signifcant source of reactive oxygen species in coronary arteries. Circ. Res. 88, 44-51 (2001).
39. Kurata, J.H., Honda, G.D. & Frankl, H. The incidence of duodenal and gastric ulcers in a large health maintenance organization. Am. J. Public Health 75, 625-629 (1985).
40. Wu, H.C., Tuo, B.G., Wu, W.M., Gao, Y., Xu, Q.Q. & Zhao, K. Prevalence of peptic ulcer in dyspeptic patients and the infuence of age, sex, and Helicobacter pylori infection. Dig. Dis. Sci. 53, 2650-2656 (2008).
41. de Martel, C. & Parsonnet, J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig. Dis. Sci. 51, 2292-2301 (2006).
42. Cribb, A.E. et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev. 15, 551-558 (2006).
43. Sangrajrang, S. et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int. J. Cancer 125, 837-843 (2009).
44. Justenhoven, C. et al. CyP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat. 115, 391-396 (2009).
45. Tanikawa, C. et al. A genome-wide association study identifes two susceptibility loci for duodenal ulcer in the Japanese population. Nat. Genet. 44, 430-434, S1 (2012).
46. Musumba, C., Pritchard, D.M. & Pirmohamed, M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment. Pharmacol. Ther. 30, 517-531 (2009).
47. Musumba C. et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 36, 48-56 (2012).
48. Laine, L. Approaches to nonsteroidal anti-infammatory drug use in the high-risk patient. Gastroenterology 120, 594-606 (2001).
49. Forrest, J.A., Finlayson, N.D. & Shearman, D.J. Endoscopy in gastrointestinal bleeding. Lancet 2, 394-397 (1974).
50. Scott, S.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CyP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).